Sign In
Buy PLRX
$1.18
+0.0200 (+1.72%)
At Close: Jun 03, 2026
Aeglea BioTherapeutics (AGLE) Seeks EU Nod for ARG1-D Treatment
04:28pm, Monday, 22'nd Aug 2022 Zacks Investment Research
Aeglea BioTherapeutics (AGLE) seeks a nod for its lead candidate, pegzilarginase, for treating ARG1-D in the European Union. Stock surges post announcement.
Pliant Therapeutics: Wait For A Better Price To Get In
06:07am, Saturday, 20'th Aug 2022
PLRX went up 200% on strong phase 2a data in IPF. Even a subsequent large dilution was unable to dampen enthusiasm.
How Much Upside is Left in Pliant Therapeutics, Inc. (PLRX)? Wall Street Analysts Think 106%
01:55pm, Monday, 15'th Aug 2022 Zacks Investment Research
The mean of analysts' price targets for Pliant Therapeutics, Inc. (PLRX) points to a 105.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agree
The Zacks Analyst Blog Highlights Absci Axcella Health, Freeline Therapeutics Holdings, DICE Therapeutics and Pliant Therapeutics
12:19pm, Wednesday, 10'th Aug 2022 Zacks Investment Research
Absci, Axcella Health, Freeline Therapeutics Holdings, DICE Therapeutics and Pliant Therapeutics are part of Zacks top Analyst Blog.
Expert Ratings for Pliant Therapeutics
04:21pm, Tuesday, 09'th Aug 2022 Benzinga
Within the last quarter, Pliant Therapeutics (NASDAQ:PLRX) has observed the following analyst ratings:
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
1
4
0
0
0
5 Biotech Stocks Likely to Outpace Q2 Earnings Estimates
11:40am, Tuesday, 09'th Aug 2022 Zacks Investment Research
Let us look at some drug/biotech stocks, ABSI, AXLA, FRLN, DICE and PLRX, which are poised to beat on second-quarter earnings.
5 Biotech Stocks Likely to Outpace Q2 Earnings Estimates
09:02am, Tuesday, 09'th Aug 2022
Let us look at some drug/biotech stocks, ABSI, AXLA, FRLN, DICE and PLRX, which are poised to beat on second-quarter earnings.
Pliant Therapeutics, Inc. (PLRX) Reports Q2 Loss, Tops Revenue Estimates
09:25pm, Monday, 08'th Aug 2022 Zacks Investment Research
Pliant Therapeutics, Inc. (PLRX) delivered earnings and revenue surprises of 0% and 269.56%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Pliant Therapeutics, Inc. (PLRX) Reports Q2 Loss, Tops Revenue Estimates
06:48pm, Monday, 08'th Aug 2022
Pliant Therapeutics, Inc. (PLRX) delivered earnings and revenue surprises of 0% and 269.56%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Amicus (FOLD) Q2 Earnings Beat, Galafold Sales Miss Estimates
03:55pm, Friday, 05'th Aug 2022 Zacks Investment Research
Amicus Therapeutics (FOLD) posts a narrower-than-expected loss for the second quarter. FOLD's sole marketed drug Galafold's solid sales drive the top line.
Intellia's (NTLA) Q2 Loss Wider Than Expected, Revenues Beat
05:43pm, Thursday, 04'th Aug 2022 Zacks Investment Research
Intellia Therapeutics (NTLA) posts a wider-than-expected Q2 loss while sales beat the mark. NTLA continues to advance its pipeline with developmental programs.
Amarin (AMRN) Q2 Earnings & Sales Hurt by Vazkepa Generics
05:05pm, Thursday, 04'th Aug 2022 Zacks Investment Research
Amarin's (AMRN) Vazkepa sales decline year over year amid rising generic competition and COVID-related disruptions during the second quarter. The company's stock witnesses a decline on Aug 3.
7 Cheap Biotech Stocks to Buy Now
04:42pm, Wednesday, 03'rd Aug 2022
Biopharmaceutical companies have been struggling since 2021 and that narrative isn't immediately changing. However, not every firm deserves this fate.
Repligen (RGEN) Q2 Earnings and Sales Beat Estimates, Stock Up
04:19pm, Wednesday, 03'rd Aug 2022 Zacks Investment Research
Repligen (RGEN) reports encouraging second-quarter results, with sales and earnings beating estimates. RGEN also raises its financial guidance for 2022
Analysts Estimate Kymera Therapeutics, Inc. (KYMR) to Report a Decline in Earnings: What to Look Out for
02:01pm, Tuesday, 02'nd Aug 2022 Zacks Investment Research
Kymera Therapeutics, Inc. (KYMR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
